Alpha 2.0
Login Register
» Authors » G Robustelli Della Cuna

G Robustelli Della Cuna

Explore the profile of G Robustelli Della Cuna including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 102
Citations 218
Followers 0
Related Specialties
Oncology
Hematology
General Medicine
Top 10 Co-Authors
L Pavesi
P Pedrazzoli
P Preti
N Gibelli
G A Da Prada
C Zibera
M Battaglia
F Bertolini
C Perotti
A Lanza
Published In
Haematologica
Bone Marrow Transplant
Anticancer Res
Minerva Med
Tumori
Affiliations
Soon will be listed here.
Recent Articles
1.
A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer
Cresta S, Grasselli G, Mansutti M, Martoni A, Lelli G, Capri G, et al.
Ann Oncol . 2004 Mar; 15(3):433-9. PMID: 14998845
Background: This randomized phase II study was conducted to evaluate the efficacy of doxorubicin and docetaxel (DOC) administered either as a combination, an alternating or a sequential regimen in women...
2.
Randomized, controlled, multicenter phase III trial of standard-dose fluorouracil-epirubicin-cyclophosphamide (FEC), compared with time-intensive FEC (FEC-G) and mitoxantrone-methotrexate-mitomycin C (MMM-G) in metastatic breast carcinoma
Capotorto A, Pavesi L, Pedrazzoli P, Da Prada G, Zamagni C, Massidda B, et al.
J Chemother . 2003 Jun; 15(2):184-91. PMID: 12797397
The purpose of this multicenter phase III trial was to assess the impact of a time-intensification of FEC (fluorouracil, epirubicin, cyclophosphamide) and MMM (mitoxantrone, methotrexate, mitomycin C) regimens, supported by...
3.
Cytotoxic chemotherapy preceding apheresis of peripheral blood progenitor cells can affect the early reconstitution phase of naive T cells after autologous transplantation
Fagnoni F, Lozza L, Zibera C, Zambelli A, Gibelli N, Oliviero B, et al.
Bone Marrow Transplant . 2003 Mar; 31(1):31-8. PMID: 12621504
Transient T cell immunodeficiency is a common complication following hematopoietic stem cell transplantation. In breast cancer patients transplanted with autologous peripheral blood progenitor cells (PBPC) harvested after cytotoxic treatment with...
4.
Cytotoxic T-lymphocyte responses in melanoma through in vitro stimulation with the Melan-A peptide analogue A27L: a qualitative analysis
Palermo B, Campanelli R, Garbelli S, Mantovani S, Cuna G, Necker A, et al.
Melanoma Res . 2002 Oct; 12(5):491-8. PMID: 12394191
Modifications in tumour antigen-derived epitopes that stabilize the major histocompatibility complex (MHC)-peptide complex result in enhanced stimulatory capacity and improved immunogenicity of the altered peptide. These epitope analogues are attractive...
5.
Multimodal treatment with primary single-agent epirubicin in operable breast cancer: 5-year experience of the Michelangelo Cooperative Group
Bonadonna G, Zambetti M, Bumma C, Donadio M, Bolognesi A, Cuna G, et al.
Ann Oncol . 2002 Aug; 13(7):1049-58. PMID: 12176783
Background: To assess the efficacy of primary single-agent epirubicin (120 mg/m(2) every 3 weeks for three cycles) in reducing tumor burden in operable breast cancer >or=2.5 cm in largest diameter...
6.
Mitomycin C as an alternative to irradiation to inhibit the feeder layer growth in long-term culture assays
Ponchio L, Duma L, Oliviero B, Gibelli N, Pedrazzoli P, Cuna G
Cytotherapy . 2002 Jun; 2(4):281-6. PMID: 12042037
Background: Mitomycin C (MMC), an antitumoral antibiotic, has been described inhibiting the proliferation of different cell types in vitro. Since irradiation is commonly used to stop the cell growth of...
7.
Prospective phase II study of single-agent gemcitabine in untreated elderly patients with stage IIIB/IV non-small-cell lung cancer
Martoni A, Di Fabio F, Guaraldi M, Piana E, Ramini R, Lelli G, et al.
Am J Clin Oncol . 2002 Jan; 24(6):614-7. PMID: 11801766
The purpose of this study was to evaluate the efficacy and tolerability of single-agent gemcitabine in untreated elderly patients with stage IIIb/IV non-small-cell lung cancer (NSCLC). Since April 1997, 46...
8.
153Sm-EDTMP radionuclide treatment of bony metastatic disease: a radiation protection evaluation
Moro L, Fantinato D, Aprile C, Preti P, Cuna G
G Ital Med Lav Ergon . 2002 Jan; 23(4):435-7. PMID: 11758146
The aims of the study were the identification and optimization of the radiation protection measures for in-patients who underwent palliative radionuclide therapy for bone metastases with 153Sm-EDTMP activities lower than...
9.
Circulating CD33+ large mononuclear cells contain three distinct populations with phenotype of putative antigen-presenting cells including myeloid dendritic cells and CD14+ monocytes with their CD16+ subset
Fagnoni F, Oliviero B, Zibera C, Gibelli N, Lozza L, Vescovini R, et al.
Cytometry . 2001 Oct; 45(2):124-32. PMID: 11590624
Background: In peripheral blood, myeloid markers identify a heterogeneous mixture of cells in transit from the bone marrow to peripheral tissues. Similarly, HLA-class II DR expression usually identifies mononuclear cells...
10.
Three conventional-drug combination (ifosfamide, carboplatin, etoposide--ICE regimen) in advanced non-small cell lung cancer (NSCLC)
Cuomo A, Robustelli Della Cuna F, Baiardi P, Torazzo R, Preti P, Cuna G
J Chemother . 2001 Oct; 13(4):434-9. PMID: 11589488
Fifty consecutive patients with stage IIIB-IV non-small cell lung cancer (NSCLC) received the ICE regimen at intermediate doses (ifosfamide 1 g/m2, carboplatin 120 mg/m2, etoposide 80 mg/m2, day 1 to...